top of page
Lecture 33: Myeloproliferative Neoplasms: : Current and Emerging Treatments
Raajit Rampal MD, PhD
Presentation Date:
May 22, 2025
> Myeloproliferative Neoplasms are a group of disorders, manifesting with increased circulating numbers of blood cells.
> Mutations and activation of the JAK-STAT pathway is the Hallmark of MPNs
Raajit Rampal MD, PhD
Clinical Director, Leukemia Service
Director, Program in MPNs and Rare Hematologic Malignancies
Disclosures
> Consulting Fees: Incyte Corporation, Celgene/BMS, Blueprint, Abbvie, CTI, Stemline, Galecto, Pharmaessentia, Constellation/Morphosys, Sierra Oncology/GSK, Cogent, Sumitomo Pharma, Kartos, Servier, Zentalis, Opna, Karyopharm.
> Research Funding: Constellation pharmaceuticals, Ryvu, Zentalis, BVD and Stemline Therapeutics.
> Peripheral smear at High Power, demonstrating increased platelets, including large forms.
> This is classical for Essential Thrombocythemia.
Starting in 2025, lectures are eligible for Continuing Education Credit.
Link for CE:
bottom of page